- In recent months, Intuitive Surgical has faced FDA safety alerts and voluntary recalls involving certain da Vinci S and Si instruments and SureForm stapler reloads, prompting added regulatory scrutiny of its robotic surgery platform.
- These safety concerns arrive just as hospitals are upgrading to the new da Vinci 5 systems and increasingly using lease structures, potentially complicating adoption decisions and contract terms.
- We’ll now examine how heightened FDA scrutiny and recall activity could reshape Intuitive Surgical’s investment narrative and key growth assumptions.
Find 47 companies with promising cash flow potential yet trading below their fair value.
Intuitive Surgical Investment Narrative Recap
To own Intuitive Surgical, you have to believe robotic-assisted surgery remains central to how hospitals deliver minimally invasive care and that the da Vinci ecosystem keeps its edge. In the near term, the key catalyst is the upgrade cycle to da Vinci 5 and associated procedure growth, while the biggest risk now is whether ongoing FDA safety alerts and recalls start to affect surgeon confidence, hospital purchasing decisions, or future regulatory requirements in a meaningful way.
The most relevant recent announcement is the cluster of voluntary FDA Class I and Class II recalls affecting certain da Vinci instruments and SureForm 30 Gray Reloads, just as Q1 2026 saw 431 system placements and heavy upgrade-driven demand. This combination ties regulatory scrutiny directly to the platform’s expansion and raises questions about how hospitals weigh safety communications against the appeal of newer systems and flexible leasing structures during the current replacement cycle.
Yet behind the system placements and upgrade story, there is a separate risk investors should be aware of around how future regulatory and pricing pressure could...
Read the full narrative on Intuitive Surgical (it's free!)
Intuitive Surgical's narrative projects $15.3 billion revenue and $4.5 billion earnings by 2029. This requires 13.1% yearly revenue growth and a $1.5 billion earnings increase from $3.0 billion today.
Uncover how Intuitive Surgical's forecasts yield a $565.25 fair value, a 36% upside to its current price.
Exploring Other Perspectives
Compared with the consensus upgrade story, the lowest analysts were already more cautious, assuming revenue of about US$13.9 billion and earnings of US$4.0 billion by 2029, and the recent recalls could give their concerns about pricing pressure and regulatory scrutiny more weight, so it is worth considering how your own view lines up with these more pessimistic assumptions.
Explore 11 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 51% more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.
Curious About Other Options?
Our top stock finds are flying under the radar-for now. Get in early:
- Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com